Front-line therapy in lung cancer with mutations in EGFR

Large randomised phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harbouring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy.

Download full article